Up to 40% of Diabetes Patients Achieved Normal HbA1c With Retatrutide

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Up to 40% of Diabetes Patients Achieved Normal HbA1c With Retatrutide

Latest News

Interpreting Kidney Donor Pregnancy Signals, With Amit Garg, MD, PhD Amit X. Garg, MD, PhD

Does CKD Require Restricting Potassium-Rich Foods? With Navdeep Tangri, MD Navdeep Tangri, MD

Pentoxifylline in Diabetic Kidney Disease: What the Evidence Shows Rajiv Agarwal, MD, MS

eGFR Underestimates CKD in Patients with Cancer, Study Finds

Counseling Kidney Donors on Future Pregnancy, With Amit Garg, MD, PhD Amit X. Garg, MD, PhD

Is Pregnancy Riskier for Living Kidney Donors? With Amit X. Garg, MD, PhD Amit X. Garg, MD, PhD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Latest News

News All Time

How Glomerular Disease Shapes Young Women's Life Choices, With Sayna Norouzi, MD Sayna Norouzi, MD

Pregnancy After Living Kidney Donation, With Amit X. Garg, MD, PhD Amit X. Garg, MD, PhD

Felzartamab and the Hidden Injury of Isolated MVI, With Yasir Qazi, MD Yasir Qazi, MD

I CAN: Ravulizumab Cuts Proteinuria 43% vs Placebo in IgA Nephropathy

Lorundrostat Lowers BP, Albuminuria in CKD With Uncontrolled Hypertension

TELIGAN: Telitacicept Preserves eGFR Through 2 Years in IgA Nephropathy Abigail Brooks, MA

IMAgINATION: Sefaxersen Meets Phase 3 Proteinuria Endpoint in IgA Nephropathy

RAINIER: Povetacicept Cuts Proteinuria, Gd-IgA1 in IgA Nephropathy

Inside FIND-CKD: The Data Behind the Trial's 23% Risk Reduction Brendon Neuen, MBBS, PhD, Shikha Wadhwani, MD, MS

Inside FIND-CKD: Can Finerenone Pair With Immunosuppression in GN? Brendon Neuen, MBBS, PhD, Shikha Wadhwani, MD, MS

Uromodulin Drop Offers Clues to SGLT2 Kidney Protection, With Greco Malijan, MD Greco Malijan, MD

New ASN Compendium Tackles Fragmented GN Care, With Vasquez-Rios, MD George Vasquez-Rios, MD

You Don't Need to Be a GN Specialist to Identify Glomerular Disease Earlier George Vasquez-Rios, MD

ASN Kidney Week 2026 Preview: 8 Late-Breakers We’ll Unpack With the Investigators

Iptacopan Maintains Kidney Benefit Through 48 Months in IgA Nephropathy

Mezagitamab, an anti-CD38 Monoclonal Antibody, Stabilizes eGFR 18 months Off Treatment in IgAN Patrick Campbell

Recommended News For You

Living near St. Louis-area Coldwater Creek during childhood linked with higher risk of cancer from radiation

The top three drugs for multiple myeloma treatment upfront are four.

Un nou sistem de endoscopică imaging are capacitatea de a detecta mai mulți fluorescent tracers.

Immunotherapy after surgery is good for patients with advanced cancer

Highly Successful Treatment of Lynch Syndrome Patients with PD-1 Inhibitors for Colorectal Cancer.

Asymptomatic or Minimally Symptomatic Myelofibrosis

EBCC: European Breast Cancer Conference

Recommended Articles For You

HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia

Revolutionizing Cancer Care: The Impact of Darzalex Faspro

Engineered Immune Cells for Brain Tumors: Mechanisms, Clinical Impact, and Future Directions

RDW-CV vs. MCV: Knowing the Difference Can Help You Better Understand Your Health

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.